• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

状态转移模型转移概率的估计:NICE 评估综述。

Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals.

机构信息

School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, S1 4DA, UK.

出版信息

Pharmacoeconomics. 2021 Aug;39(8):869-878. doi: 10.1007/s40273-021-01034-5. Epub 2021 May 19.

DOI:10.1007/s40273-021-01034-5
PMID:34008137
Abstract

State transition models are used to inform health technology reimbursement decisions. Within state transition models, the movement of patients between the model health states over discrete time intervals is determined by transition probabilities (TPs). Estimating TPs presents numerous issues, including missing data for specific transitions, data incongruence and uncertainty around extrapolation. Inappropriately estimated TPs could result in biased models. There is limited guidance on how to address common issues associated with TP estimation. To assess current methods for estimating TPs and to identify issues that may introduce bias, we reviewed National Institute for Health and Care Excellence Technology Appraisals published from 1 January, 2019 to 27 May, 2020. Twenty-eight models (from 26 Technology Appraisals) were included in the review. Several methods for estimating TPs were identified: survival analysis (n = 11); count method (n = 9); multi-state modelling (n = 7); logistic regression (n = 2); negative binomial regression (n = 2); Poisson regression (n = 1); and calibration (n = 1). Evidence Review Groups identified several issues relating to TP estimation within these models, including important transitions being excluded (n = 5); potential selection bias when estimating TPs for post-randomisation health states (n = 2); issues concerning the use of multiple data sources (n = 4); potential biases resulting from the use of data from different populations (n = 2), and inappropriate assumptions around extrapolation (n = 3). These issues remained unresolved in almost every instance. Failing to address these issues may bias model results and lead to sub-optimal decision making. Further research is recommended to address these methodological problems.

摘要

状态转移模型用于为医疗技术报销决策提供信息。在状态转移模型中,患者在离散时间间隔内在模型健康状态之间的移动由转移概率 (TP) 决定。估计 TP 存在许多问题,包括特定转移的缺失数据、数据不一致和外推不确定性。估计不当的 TP 可能导致模型产生偏差。关于如何解决与 TP 估计相关的常见问题,指南有限。为了评估目前用于估计 TP 的方法并确定可能引入偏差的问题,我们审查了 2019 年 1 月 1 日至 2020 年 5 月 27 日发布的国家卫生与保健卓越研究所技术评估。审查包括 28 个模型(来自 26 个技术评估)。确定了几种估计 TP 的方法:生存分析 (n = 11);计数法 (n = 9);多状态建模 (n = 7);逻辑回归 (n = 2);负二项式回归 (n = 2);泊松回归 (n = 1);以及校准 (n = 1)。证据审查组在这些模型中确定了与 TP 估计相关的几个问题,包括重要的转移被排除 (n = 5);在估计随机化后健康状态的 TP 时可能存在选择偏差 (n = 2);关于使用多个数据源的问题 (n = 4);由于使用来自不同人群的数据而导致的潜在偏差 (n = 2),以及外推方面的不适当假设 (n = 3)。在几乎所有情况下,这些问题都没有得到解决。未能解决这些问题可能会使模型结果产生偏差,并导致决策不理想。建议进一步研究以解决这些方法问题。

相似文献

1
Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals.状态转移模型转移概率的估计:NICE 评估综述。
Pharmacoeconomics. 2021 Aug;39(8):869-878. doi: 10.1007/s40273-021-01034-5. Epub 2021 May 19.
2
How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017.制药公司如何对癌症患者的生存情况进行建模?对 2017 年 NICE 单一技术评估的回顾。
Int J Technol Assess Health Care. 2019 Jan;35(2):160-167. doi: 10.1017/S0266462319000175.
3
Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making.抗癌药物提交给英国国家卫生与临床优化研究所的不成熟生存数据的流行情况及其对决策的影响。
Value Health. 2021 Apr;24(4):505-512. doi: 10.1016/j.jval.2020.10.016. Epub 2020 Dec 8.
4
A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?英国国家卫生与临床优化研究所对癌症免疫疗法卫生技术评估中总生存外推法的回顾与验证:最初的最佳估计与随后可得的试验数据相比如何?
J Med Econ. 2019 Mar;22(3):205-214. doi: 10.1080/13696998.2018.1547303. Epub 2018 Nov 30.
5
Probabilistic analysis and computationally expensive models: Necessary and required?概率分析与计算成本高昂的模型:必要且必需吗?
Value Health. 2006 Jul-Aug;9(4):244-52. doi: 10.1111/j.1524-4733.2006.00107.x.
6
Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.在英国国家卫生与临床优化研究所(NICE)技术评估中的效用值。
Value Health. 2011 Jan;14(1):102-9. doi: 10.1016/j.jval.2010.10.015.
7
Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?肿瘤学中用于医疗保健决策的分区生存和状态转移模型:我们现在在哪里?
Value Health. 2020 Dec;23(12):1613-1621. doi: 10.1016/j.jval.2020.08.2094. Epub 2020 Oct 17.
8
Treatment Effect Waning Assumptions: A Review of National Institute of Health and Care Excellence Technology Appraisals.治疗效果衰减假设:国家卫生与保健卓越研究所技术评估综述。
Value Health. 2024 Aug;27(8):1003-1011. doi: 10.1016/j.jval.2024.04.016. Epub 2024 Apr 26.
9
Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers.从已发表证据中估计转移概率:决策模型构建者的教程。
Pharmacoeconomics. 2020 Nov;38(11):1153-1164. doi: 10.1007/s40273-020-00937-z.
10
Analysis of factors associated with use of real-world data in single technology appraisals of cancer drugs by the National Institute for Health and Care Excellence.分析与英国国家卫生与保健优化研究所(NICE)癌症药物单项技术评估中使用真实世界数据相关的因素。
J Cancer Policy. 2024 Dec;42:100507. doi: 10.1016/j.jcpo.2024.100507. Epub 2024 Sep 26.

引用本文的文献

1
Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications.从一个超过6000人的澳大利亚多发性硬化症(MS)患者大队列中估计残疾严重程度分类、MS表型和疾病修正治疗分类变化的转移概率。
Pharmacoeconomics. 2025 Feb;43(2):223-239. doi: 10.1007/s40273-024-01417-4. Epub 2024 Aug 2.
2
Childhood Transitions Between Weight Status Categories: Evidence from the UK Millennium Cohort Study.儿童体重状况类别间的转变:来自英国千禧年队列研究的证据。
Pharmacoeconomics. 2024 Jun;42(6):649-661. doi: 10.1007/s40273-024-01361-3. Epub 2024 Apr 3.
3

本文引用的文献

1
Current recommendations on the estimation of transition probabilities in Markov cohort models for use in health care decision-making: a targeted literature review.用于医疗保健决策的马尔可夫队列模型中转移概率估计的当前建议:一项针对性文献综述
Clinicoecon Outcomes Res. 2017 Sep 1;9:537-546. doi: 10.2147/CEOR.S135445. eCollection 2017.
2
Why post-progression survival and post-relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials.为何进展后生存期和复发后生存期并非癌症随机临床试验中疗效的恰当衡量指标。
Int J Cancer. 2015 May 15;136(10):2444-7. doi: 10.1002/ijc.29278. Epub 2014 Nov 3.
3
A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales.
在英格兰和威尔士,辅助使用大麻二酚与单纯常规护理治疗结节性硬化症相关癫痫发作的成本效用分析。
Pharmacoecon Open. 2024 Jul;8(4):611-626. doi: 10.1007/s41669-024-00474-x. Epub 2024 Mar 5.
4
Estimating Transition Probabilities for Modeling Major Depression in Adolescents by Sex and Race or Ethnicity Combinations in the USA.估计美国青少年中性别和种族或族裔组合的主要抑郁症建模的转移概率。
Appl Health Econ Health Policy. 2024 May;22(3):375-390. doi: 10.1007/s40258-024-00872-6. Epub 2024 Jan 22.
5
Association of cigarette excise taxes and clean indoor air laws with change in smoking behavior in the United States: a Markov modeling analysis.美国香烟消费税和室内清洁空气法与吸烟行为变化的关联:一项马尔可夫模型分析
J Public Health Policy. 2024 Mar;45(1):100-113. doi: 10.1057/s41271-023-00458-x. Epub 2023 Dec 28.
6
Comparative analysis of disease modelling for health economic evaluations of systemic therapies in advanced hepatocellular carcinoma.比较分析系统治疗晚期肝细胞癌的卫生经济评价中的疾病建模。
PLoS One. 2023 Oct 5;18(10):e0292239. doi: 10.1371/journal.pone.0292239. eCollection 2023.
7
Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin's lymphoma.伴随 inter-B-NHL ritux 2010 试验的成本效益分析:利妥昔单抗治疗儿童和青少年 B 细胞非霍奇金淋巴瘤。
Eur J Health Econ. 2024 Mar;25(2):307-317. doi: 10.1007/s10198-023-01581-y. Epub 2023 Apr 14.
8
Modeling Posttreatment Prognosis of Skin Lesions in Patients With Psoriasis in China.中国银屑病患者治疗后皮损预后模型研究。
JAMA Netw Open. 2023 Apr 3;6(4):e236795. doi: 10.1001/jamanetworkopen.2023.6795.
State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3.
状态转移建模:ISPOR-SMDM 建模良好实践工作组的报告——3。
Value Health. 2012 Sep-Oct;15(6):812-20. doi: 10.1016/j.jval.2012.06.014.
4
Tutorial in biostatistics: competing risks and multi-state models.生物统计学教程:竞争风险与多状态模型
Stat Med. 2007 May 20;26(11):2389-430. doi: 10.1002/sim.2712.
5
Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis.随机分组后的排除标准:意向性分析原则及将患者排除在分析之外。
BMJ. 2002 Sep 21;325(7365):652-4. doi: 10.1136/bmj.325.7365.652.
6
An introduction to Markov modelling for economic evaluation.经济评估中的马尔可夫模型介绍。
Pharmacoeconomics. 1998 Apr;13(4):397-409. doi: 10.2165/00019053-199813040-00003.
7
Modelling in economic evaluation: an unavoidable fact of life.经济评估中的建模:生活中不可避免的事实。
Health Econ. 1997 May-Jun;6(3):217-27. doi: 10.1002/(sici)1099-1050(199705)6:3<217::aid-hec267>3.0.co;2-w.